AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders.

Technology Overview

AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera has developed specific antibody discovery and development technologies to unlock high-value drug classes and targets, including T-cell engagers for cancer and transmembrane proteins for indications including metabolic and endocrine conditions, pain, autoimmunity and more.


"In recent years we have made a series of investments into the next generation of therapeutic antibodies. We are seeing a wave of innovation in the antibody space that is allowing us to add novel functionalities to these molecules. Our partnership with AbCellera will further enable our portfolio companies to pursue these important biologic medicines.”
Markus Enzelberger, Ph.D., Versant partner
"This collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer. We are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology."
Patrick Mayes, Ph.D., Vice President, BioTherapeutics at Incyte
“I am pleased to see AbCellera participating in our government’s effort to reverse a four-decade decline in Canada’s domestic capacity. This is an important step toward improving Canada’s pandemic preparedness, and a driver for our economic recovery.”
François-Philippe Champagne, minister of innovation, science and industry, quote from Endpoints
"We continue to be impressed with the speed of discovery, the quality, and the diversity of the antibodies AbCellera delivers. Through this agreement, we have secured expanded access to an industry-leading technology to accelerate the discovery of antibody-based therapies for patients with neurological diseases."
Alexander Schuth, COO